{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "LFIA",
      "SARS-CoV-2",
      "antibody",
      "nucleocapsid protein",
      "rapid test"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34830291",
  "DateCompleted": {
    "Year": "2021",
    "Month": "12",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "12",
    "Day": "14"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "11",
        "Day": "17"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "12412",
      "10.3390/ijms222212412"
    ],
    "Journal": {
      "ISSN": "1422-0067",
      "JournalIssue": {
        "Volume": "22",
        "Issue": "22",
        "PubDate": {
          "Year": "2021",
          "Month": "Nov",
          "Day": "17"
        }
      },
      "Title": "International journal of molecular sciences",
      "ISOAbbreviation": "Int J Mol Sci"
    },
    "ArticleTitle": "Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19.",
    "Abstract": {
      "AbstractText": [
        "Mitigation strategies of the coronavirus disease 2019 (COVID-19) pandemic have been greatly hindered by the continuous emergence of SARS-CoV-2 variants. New sensitive, rapid diagnostic tests for the wide-spectrum detection of viral variants are needed. We generated a panel of 41 monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein (NP) by using mice hybridoma techniques. Of these mAbs, nine exhibited high binding activities and were applied in latex-based lateral flow immunoassays (LFIAs). The LFIAs utilizing NP-mAb-7 and -40 had the best sensitivity and lowest limit of detection: 8 pg for purified NP and 625 TCID<sub>50</sub>/mL for the authentic virus (hCoV-19/Taiwan/4/2020). The specificity tests showed that the NP-mAb-40/7 LFIA strips did not cross-react with five human coronavirus strains or 20 other common respiratory pathogens. Importantly, we found that 10 NP mutants, including alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) variants, could be detected by NP-mAb-40/7 LFIA strips. A clinical study (<i>n</i> = 60) of the NP-mAb-40/7 LFIA strips demonstrated a specificity of 100% and sensitivity of 90% in infected individuals with cycle threshold (Ct) values < 29.5. These anti-NP mAbs have strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-3792-5499"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei 11529, Taiwan."
          }
        ],
        "LastName": "Lu",
        "ForeName": "Ruei-Min",
        "Initials": "RM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei 11529, Taiwan."
          }
        ],
        "LastName": "Ko",
        "ForeName": "Shih-Han",
        "Initials": "SH"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan."
          }
        ],
        "LastName": "Chen",
        "ForeName": "Wan-Yu",
        "Initials": "WY"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei 11529, Taiwan."
          }
        ],
        "LastName": "Chang",
        "ForeName": "Yu-Ling",
        "Initials": "YL"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan."
          }
        ],
        "LastName": "Lin",
        "ForeName": "Hsiu-Ting",
        "Initials": "HT"
      },
      {
        "Identifier": [
          "0000-0002-5185-1169"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei 11529, Taiwan."
          },
          {
            "Identifier": [],
            "Affiliation": "Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan."
          }
        ],
        "LastName": "Wu",
        "ForeName": "Han-Chung",
        "Initials": "HC"
      }
    ],
    "GrantList": [
      {
        "GrantID": "[MOST- 108-3114-Y-001-002], [MOST-108-2823-8-001-001], and [MOST 109-3114-Y- 001-001]",
        "Agency": "Ministry of Science and Technology, Taiwan",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Int J Mol Sci",
    "NlmUniqueID": "101092791",
    "ISSNLinking": "1422-0067"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Monoclonal"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Nucleocapsid Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Antibodies, Monoclonal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Antigen-Antibody Reactions"
    },
    {
      "QualifierName": [
        "diagnosis",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Coronavirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cross Reactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Immunoassay"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Nucleocapsid Proteins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Point-of-Care Systems"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Real-Time Polymerase Chain Reaction"
    },
    {
      "QualifierName": [
        "genetics",
        "isolation & purification",
        "metabolism"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Young Adult"
    }
  ],
  "CoiStatement": "Related to the Acadecise antigen rapid test, Academia Sinica has received an EUA from the TFDA. Academia Sinica has material transfer agreements (MTAs) for anti-NP mAbs with Panion & BF Biotech Inc., and it has commissioned Panion & BF Biotech Inc. to develop and produce Acadecise antigen rapid test kits. The individual authors in this study declare no conflict of interest."
}